253 related articles for article (PubMed ID: 30904971)
21. An integrated virtual screening approach for VEGFR-2 inhibitors.
Zhang Y; Yang S; Jiao Y; Liu H; Yuan H; Lu S; Ran T; Yao S; Ke Z; Xu J; Xiong X; Chen Y; Lu T
J Chem Inf Model; 2013 Dec; 53(12):3163-77. PubMed ID: 24266594
[TBL] [Abstract][Full Text] [Related]
22. Discovery of VEGFR inhibitors through virtual screening and energy assessment.
Reang J; Sharma K; Sharma PC; Yadav V; Sharma V; Majeed J
J Biochem Mol Toxicol; 2023 May; 37(5):e23321. PubMed ID: 36808794
[TBL] [Abstract][Full Text] [Related]
23. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
24. Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations.
Rampogu S; Baek A; Zeb A; Lee KW
BMC Cancer; 2018 Mar; 18(1):264. PubMed ID: 29514608
[TBL] [Abstract][Full Text] [Related]
25. Discovery of new 4-alkoxyquinazoline-based derivatives as potent VEGFR2 inhibitors.
Yin Y; Sha S; Wang YT; Wu X; Wang SF; Qiao F; Lv PC; Zhu HL
Chem Biol Drug Des; 2015 Nov; 86(5):1323-9. PubMed ID: 26032487
[TBL] [Abstract][Full Text] [Related]
26. Molecular dynamics-based insight of VEGFR-2 kinase domain: a combined study of pharmacophore modeling and molecular docking and dynamics.
Parves MR; Riza YM; Alam S; Jaman S
J Mol Model; 2022 Dec; 29(1):17. PubMed ID: 36550239
[TBL] [Abstract][Full Text] [Related]
27. Discovery of novel vascular endothelial growth factor receptor 2 inhibitors: a virtual screening approach.
Zhang L; Wang X; Feng J; Jia Y; Xu F; Xu W
Chem Biol Drug Des; 2012 Dec; 80(6):893-901. PubMed ID: 22913881
[TBL] [Abstract][Full Text] [Related]
28. The unbinding studies of vascular endothelial growth factor receptor-2 protein tyrosine kinase type II inhibitors.
Kang CM; Liu DQ; Wang XY; Yu RL; Lv YT
J Mol Graph Model; 2015 Jun; 59():130-5. PubMed ID: 25989626
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological evaluation of novel oxazolo[5,4-d]pyrimidines as potent VEGFR-2 inhibitors.
Deng YH; Xu D; Su YX; Cheng YJ; Yang YL; Wang XY; Zhang J; You QD; Sun LP
Chem Biodivers; 2015 Apr; 12(4):528-37. PubMed ID: 25879498
[TBL] [Abstract][Full Text] [Related]
30. Discovery of novel taspine derivatives as antiangiogenic agents.
Zhang J; Zhang Y; Zhang S; Wang S; He L
Bioorg Med Chem Lett; 2010 Jan; 20(2):718-21. PubMed ID: 20006929
[TBL] [Abstract][Full Text] [Related]
31. In silico discovery of potential VEGFR-2 inhibitors from natural derivatives for anti-angiogenesis therapy.
Li J; Zhou N; Luo K; Zhang W; Li X; Wu C; Bao J
Int J Mol Sci; 2014 Sep; 15(9):15994-6011. PubMed ID: 25216334
[TBL] [Abstract][Full Text] [Related]
32. Discovery of novel tricyclic pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amine derivatives as VEGFR-2 inhibitors.
Abdel Aziz YM; Said MM; El Shihawy HA; Abouzid KA
Bioorg Chem; 2015 Jun; 60():1-12. PubMed ID: 25899678
[TBL] [Abstract][Full Text] [Related]
33. Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.
Lee K; Jeong KW; Lee Y; Song JY; Kim MS; Lee GS; Kim Y
Eur J Med Chem; 2010 Nov; 45(11):5420-7. PubMed ID: 20869793
[TBL] [Abstract][Full Text] [Related]
34. QSAR and molecular docking studies on oxindole derivatives as VEGFR-2 tyrosine kinase inhibitors.
Kang CM; Liu DQ; Zhao XH; Dai YJ; Cheng JG; Lv YT
J Recept Signal Transduct Res; 2016; 36(1):103-9. PubMed ID: 26416217
[TBL] [Abstract][Full Text] [Related]
35. Assessing an ensemble docking-based virtual screening strategy for kinase targets by considering protein flexibility.
Tian S; Sun H; Pan P; Li D; Zhen X; Li Y; Hou T
J Chem Inf Model; 2014 Oct; 54(10):2664-79. PubMed ID: 25233367
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in structure-based drug design and virtual screening of VEGFR tyrosine kinase inhibitors.
Hoi PM; Li S; Vong CT; Tseng HH; Kwan YW; Lee SM
Methods; 2015 Jan; 71():85-91. PubMed ID: 25239735
[TBL] [Abstract][Full Text] [Related]
37. Design, Synthesis and Biological Evaluation of Uracil Derivatives as Novel VEGFR-2 Inhibitors.
Liang J; Li X; Yang S; He X; Wang M; Meng F
Curr Pharm Des; 2018; 24(6):734-740. PubMed ID: 29384056
[TBL] [Abstract][Full Text] [Related]
38. Pharmacophore based 3D-QSAR modeling and free energy analysis of VEGFR-2 inhibitors.
Rajagopalan M; Balasubramanian S; Ramaswamy A; Mathur PP
J Enzyme Inhib Med Chem; 2013 Dec; 28(6):1236-46. PubMed ID: 23061928
[TBL] [Abstract][Full Text] [Related]
39. Fragment-based investigation of thiourea derivatives as VEGFR-2 inhibitors: a cross-validated approach of ligand-based and structure-based molecular modeling studies.
Banerjee S; Kejriwal S; Ghosh B; Lanka G; Jha T; Adhikari N
J Biomol Struct Dyn; 2024; 42(2):1047-1063. PubMed ID: 37029768
[TBL] [Abstract][Full Text] [Related]
40. Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations.
Shen M; Zhou S; Li Y; Pan P; Zhang L; Hou T
Mol Biosyst; 2013 Mar; 9(3):361-74. PubMed ID: 23340525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
